Tranzactioneaza Adverum Biotechnologies (US.ADVM) - 7.9 USD (%) Tranzactioneaza

1D
1W
1M
3M
6M
1Y
5Y
Max

Indici

Bid 7.840 USD
Ask 7.980 USD
Minim 7.940 USD
Maxim 8.090 USD
Pret referinta 7.930
Volum -
Volum ultima zi 1
Max 52 sapt 17.650 USD
Min 52 sapt 0.753 USD

Descriere companie

Adverum Biotechnologies, Inc. (https://adverum.com/) is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.

Informatii companie

Nume

ADVERUM BIOTECHNOLOGIES